NEW YORK–(BUSINESS WIRE)–$PRCT #classactionlawsuit–The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, inclusive (“the Class Period”).
If you suffered a loss on your Procept investments, you have until September 22, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadline. If you choose to take no action, you may remain an absent class member. For more information about the lawsuit:
[CONTACT THE FIRM IF YOU SUFFERED A LOSS]
What Is This Lawsuit About? The lawsuit alleges that Procept made materially false and misleading statements and/or failed to disclose: (i) that during the Class Period, Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand; (ii) that Procept’s undisclosed discount program had artificially and unsustainably inflated the Company’s reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (iii) that Procept’s undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time; (iv) that Procept’s consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept’s customer base, amounting to more than 10,000 excess units by the end of the Class Period; (v) that, as a result of the foregoing, Defendants’ representations during the Class Period regarding Procept’s handpiece unit sales and the utilization of Procept’s field Systems were materially overstated; (vi) that, as a result of the foregoing, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm; and (vii) that, as a result of the foregoing, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis.
On August 6, 2025, Procept announced earnings results for its second fiscal quarter of 2025, revealing that handpiece unit shipments had unexpectedly deteriorated as the Company has sold approximately 12,750 handpieces in the U.S. during the quarter. That same day, Procept announced it expected to ship 13,350 units the following quarter, down from consensus estimates of over 13,840 units. Additionally, CEO Reza Zadno announced that Procept was eliminating the role of Chief Commercial Officer. On this news, Procept’s stock price fell from $45.69 per share on August 6, 2025 to close at $38.41 per share on August 8, 2025, a decline of approximately 16%.
On November 4, 2025, Procept announced earnings results for its third fiscal quarter of 2025, revealing that the Company had sold 13,225 handpieces, missing the Company’s guidance set during the previous quarter. The Company also announced it was reducing its annual handpiece sales guidance by 1,000 units, from 53,000 to 52,000 units. Additionally, when pressed by analysts
regarding the lowered handpiece guidance, CEO Larry L. Wood admitted that Procept had not “been managing customer inventory by establishing par levels” and that some customers were “probably carrying too much.” On this news, Procept’s stock price fell from $35.02 per share on November 4, 2025 to close at $31.30 per share on November 6, 2026, a decline of over 10%.
On February 25, 2026, Procept announced earnings results for its fourth fiscal quarter and year, revealing that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023, a differential that had grown over time, resulting in cumulative excess field inventory of over 10,000 units. As a result, Procept handpiece unit sales in the U.S. declined from 13,225 units in the third quarter to 9,400 units in the fourth quarter, a nearly 30% decline. Additionally, Procept revealed that the Company was eliminating a longstanding (but previously undisclosed) discount program that had incentivized customers to place bulk orders “[during] the final weeks” of every quarter, impairing the Company’s ability to make additional handpiece sales in subsequent quarters. On this news, Procept’s stock price fell over two trading days, from $27.84 per share on February 25, 2026 to close at $22.69 per share on February 27, 2026, a decline of over 18%.
[LEARN MORE ABOUT THE LAWSUIT]
The Lead Plaintiff Appointment Process. The federal securities laws permit any investor who acquired eligible securities during the class period to seek appointment as lead plaintiff in a class action lawsuit. Learn more about the lead plaintiff process and eligibility requirements here. Courts typically appoint the investor(s) with the largest financial loss in the case and the ability to represent the class rather than investors with simply the largest investment portfolio. Courts regularly appoint individual investors, whether acting alone or as a group, as lead plaintiffs. The rights of any investor who bought shares during the class period are generally already protected. However, lead plaintiffs have the power to influence case strategy and have a say in settlement decisions, as well as decisions concerning allocation of settlement funds among class members.
[LEARN MORE ABOUT THE LEAD PLAINTIFF PROCESS]
What Should I Do? If you purchased or otherwise acquired Procept securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
[email protected]
